Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PCVX heads into its November 4 earnings date with short sellers trimming positions, analyst conviction holding firm, and retail attention running at an unusually elevated level.
Short interest, at 12.3% of free float, remains genuinely high for a clinical-stage biotech. But the direction of travel has shifted. Shorts cut exposure by just over 2% on the week to roughly 16.1 million shares, and the month-long build that pushed SI up nearly 9.5% from late August has stalled. The borrow market tells the same story: cost to borrow is a modest 0.58%, and availability has expanded sharply to 1,324%, nearly seven times the shares available relative to those already borrowed. There is no squeeze pressure here, and any short wanting to build a new position faces few obstacles. Options positioning adds a further wrinkle. The put/call ratio, at 2.21, sits slightly below its 20-day average of 2.26, making it one of the least defensive readings in recent weeks, a subtle shift away from the persistent downside hedging that dominated through September. The ORTEX short score eased from a recent peak of 65.3 on September 29 to 63.4 on October 2, its lowest reading in the tracked period, suggesting bears are gently backing off.
The Street, by contrast, remains firmly in the bull camp. Guggenheim raised its price target to $125 from $116 on October 5 while maintaining its Buy rating. That followed a modest trim from B of A Securities last week to $130 from $133, though the firm kept its Buy. Needham reiterated Buy at $110 late September. The mean target across analysts is $109.67, roughly double the current price of $56.48, a gap that reflects the binary nature of the VAX-31 pneumococcal vaccine opportunity rather than near-term earnings momentum. Goldman Sachs initiated with Neutral and a $38 target in September 2025, a notable outlier given the stock has since traded well through that level, so that entry may be somewhat stale as context. Bulls point to VAX-31's broad serotype coverage and precise coupling technology as structural advantages over existing PCV franchises. Bears cite the recent CDC decision to recommend fewer vaccines as a potential demand headwind, and the inherent risk that immunogenicity thresholds impose on any eventual approval. Valuation multiples are negative across the board, as expected for a pre-revenue biotech, and offer little analytical traction.
Institutional ownership adds a layer of support that is less common at this stage of development. FMR (Fidelity) added 2.86 million shares in the latest reported period to hold 12.9% of the company. T. Rowe Price added 2.1 million shares to reach 10.2%. Janus Henderson at 12.1% and RA Capital at 7.7% round out a concentrated register of specialist and long-only names. The ownership profile is notably stable and growth-oriented, with the largest holders adding rather than trimming, which partly explains why the lending pool remains so deep despite the elevated headline short interest.
Insider activity over the past 30 days is worth contextualising carefully. The September 8 cluster of Form F transactions, covering the CEO, CFO, Chief Technical Operations Officer, COO and CAO, totalling just over $2.3 million, reflects tax withholding on vested shares rather than open-market selling. These are compensation mechanics, not bearish signals. The COO's October 1 sale of 2,155 shares worth around $122,000 was made under a pre-arranged 10b5-1 plan, again a routine disposal. The September 9 sale of 1,334 shares by the COO at $59.52 was not flagged as a plan sale, though the dollar amount is small enough to treat as background noise.
One detail from alt data deserves a mention. Wikipedia and ORTEX page-view data show retail attention for Vaxcyte running at a z-score of 4.6 against its own 90-day history, a sharp spike relative to what has been a quiet information flow around the name. That elevated attention does not carry a measured relationship to revenues or any operating KPI, so it cannot be read as a forward indicator. But a retail attention spike 30 days before an earnings date, combined with a short interest position that remains at 12.3% of float, does set up an interesting dynamic heading into the November 4 print.
The earnings history over the past four quarters shows consistent positive reactions. Three of the last four days-one moves were gains, averaging roughly 4% on the day. The most recent print in August produced a 7.7% one-day gain and a 9.1% five-day gain, the strongest single-report reaction in the record. What to watch in the weeks ahead is whether short sellers continue to pare back ahead of the event, or whether the elevated retail attention and improving short-score readings attract enough renewed bear pressure to push SI back toward its recent highs.
See the live data behind this article on ORTEX.
Open PCVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
